22 June 2020
The number of production sites manufacturing pharmaceutical substances in Russia has reached 95, having increased by almost 80% between 2015 and 2019, First Deputy Minister of Industry and Trade Sergey Tsyb shared during the conference “Pharmaceutical Industry in 2020” on June 17.
In the five-year period between 2015 and 2019, the nomenclature of bioactive substances produced in Russia increased by 60%, and the number of Russian manufacturing sites specializing in pharmaceutical substances by nearly 80%. The expanded manufacturing capabilities allow for deeper localization of production and make it possible to regulate medication costs throughout the production cycle, improving the competitiveness of Russian companies.
According to Tsyb, during the COVID-19 pandemic, the Ministry together with FSI SID & GP and other market operators is carrying out a comprehensive review of pharmaceuticals from the list of essential drugs that are not produced in Russia to identify prospects for import replacement. “We are analyzing our national technological capabilities with a view to organize the production of these medications in Russia,” Tsyb said.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024